Sirnaomics Ltd. (2257.HK)

4.280 0.000 (0.00%) At close: 04:08PM HKT

Sirnaomics Ltd.

Hopewell Centre
46th Floor 183 Queen’s Road East
Wan Chai
Hong Kong

https://www.sirnaomics.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 145

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Yang Lu Ph.D.	CEO, President & Chairman	4.18M	N/A	1956
Dr. David Mark Evans Ph.D.	Head of Drug Discovery & Collaboration	2.08M	N/A	1963
Dr. Xiaochang Dai Ph.D.	Senior Advisor - Drug Development & Commercialization and Executive Director	2.62M	N/A	1964
Mr. John Buergenthal	Vice President of Human Resources	N/A	N/A	N/A
Dr. Yongxiang Wang	Chief Production Officer	N/A	N/A	1953
Mr. Ting Cheung Leung CPA	Company Secretary	N/A	N/A	1984

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in HKD.

Description

Sirnaomics Ltd., an RNA therapeutics biopharmaceutical company, discovers and develops product candidates for indications with medical needs. The company's therapeutics products focus on oncology and fibrosis, anticoagulant therapies, cardiometabolic disease, complement-mediated diseases, medical aesthetics, and viral infections. Its lead drug candidates include STP705 for the treatment of non-melanoma skin cancer and for focal fat reduction; and STP707 to treat solid tumors. The company is also developing STP355 for the treatment of multiple solid tumors, including breast cancer, melanoma, and colorectal cancer; STP369 to treat head and neck and bladder cancer; STP705 for focal fat reduction; STP122G to treat coagulation disorders; STP125G to treat hypertriglyceridemia; and STP144G for the treatment of complement diseases. In addition, it is developing RV-1730, a Covid-19 vaccine; RV-1770, a respiratory syncytial virus vaccine; STP247G, STP144G, STP145G, and STP146G for the treatment of complement diseases; STP152G for ATTR amyloidosis indication; STP136G to treat hypertension; STP251G for treating hemochromatosis and hypertriglyceridemia; and STP237G to treat hypertension and hypertriglyceridemia. The company was founded in 2007 and is based in Wan Chai, Hong Kong.

Corporate governance

Sirnaomics Ltd.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.